Bod builds cannabis brands

LISTED Australian natural health and cosmetics company Bod Australia has announced it has begun formulating a range of cannabis-based topical creams and cosmetics through its partnership with Swiss cannabis extracts manufacturer Linnea, signed just last month (W 24 Oct).

Alongside the new cosmetics, Bod is currently in the process of setting up a Phase-I clinical trial of cannabis-based medicines treating a range of medical conditions, including epilepsy, chemotherapyinduced nausea and vomiting, as well as multiple sclerosis.

Unlike some other companies joining what some perceive as the medicinal cannabis “gold rush,” Bod Australia already has an established revenue-generating business as the official Australian distributor for Pommade Divine, pharmacy-only skincare products Uber Secrets and BIOEFFECT, and also produces a range of non cannabis natural medicines including Pinpoint and Flexofytol that are currently sold through Australian supermarkets and pharmacies.

The company has also established distribution agreements for these products with national retailers and pharmacy banners, including Priceline, API, Ritchie’s IGA, Good Price Pharmacy, Romeo’s Retail Group, Drakes, and in-flight sales on Virgin Australia.

Bod anticipates releasing its first cannabis-based topical treatments next year, with its forward planning relying on projections of the global skincare market reaching $233.7 billion by 2022 and the medicinal cannabis market growing to $72.8 billion by 2025.